Castrate-resistant prostate cancer: therapeutic strategies.
Harzstark
Andrea L
AL
University of California, Urologic Oncology, San Francisco, CA 94143, USA.Andrea.harzstark@ucsf.edu
Small
Eric J
EJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D000074324:Ipilimumab